Verge Genomic’s AI-Designed ALS Drug Hits the Clinic for Testing

November 3, 2022

Verge Genomics has announced that the first patient in a phase I clinical trial has taken the company’s experimental small molecule drug VRG50635 for amyotrophic lateral sclerosis (ALS). The drug is the first for the company, as its early development was primarily performed using its ConVERGE artificial intelligence (AI) platform.

According to Verge’s CEO Alice Zhang, “We are proud to be not just one of the few AI-driven biotech companies to have made it to the clinical stage, but also one of the first to bring forward a novel clinical compound against a novel target, that was entirely discovered and developed internally on our platform. Advancing VRG50635 from research to clinic in just four years offers clear proof of our team’s commitment to disciplined execution and is a leading indicator of the potential efficiency gains from tech-enabled drug discovery.”

To read more, click here.

(Source: PharmaPhorum, October 31st, 2022)

Share This Story!